Technical Analysis for BPTH - Bio-Path Holdings Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.94 | -0.60% | -0.03 |
BPTH closed down 0.6 percent on Tuesday, July 14, 2020, on 74 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical BPTH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -0.60% | |
| Bollinger Band Squeeze | Range Contraction | -0.60% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.
Biotechnology Solid Tumors Breast Cancer Lymphoma Cell Biology Therapeutic Products Oncogenes Apoptosis Blood Cancers
Biotechnology Solid Tumors Breast Cancer Lymphoma Cell Biology Therapeutic Products Oncogenes Apoptosis Blood Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.79 |
| 52 Week Low | 2.9203 |
| Average Volume | 86,488 |
| 200-Day Moving Average | 6.81 |
| 50-Day Moving Average | 5.21 |
| 20-Day Moving Average | 5.09 |
| 10-Day Moving Average | 5.09 |
| Average True Range | 0.29 |
| ADX | 15.95 |
| +DI | 17.08 |
| -DI | 16.19 |
| Chandelier Exit (Long, 3 ATRs ) | 4.68 |
| Chandelier Exit (Short, 3 ATRs ) | 5.67 |
| Upper Bollinger Band | 5.24 |
| Lower Bollinger Band | 4.93 |
| Percent B (%b) | 0.02 |
| BandWidth | 6.10 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0091 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.17 | ||||
| Resistance 3 (R3) | 5.15 | 5.05 | 5.13 | ||
| Resistance 2 (R2) | 5.05 | 4.99 | 5.06 | 5.12 | |
| Resistance 1 (R1) | 5.00 | 4.96 | 5.02 | 5.02 | 5.11 |
| Pivot Point | 4.90 | 4.90 | 4.91 | 4.91 | 4.90 |
| Support 1 (S1) | 4.84 | 4.84 | 4.86 | 4.86 | 4.77 |
| Support 2 (S2) | 4.74 | 4.80 | 4.75 | 4.76 | |
| Support 3 (S3) | 4.69 | 4.74 | 4.75 | ||
| Support 4 (S4) | 4.71 |
